How The Failure Of US PBM Reform Shaped Sanofi’s Decision To Exit Diabetes R&D
And how in contrast, Novo Nordisk is launching its oral GLP-1 agonist for diabetes at a price that may set up 'business as usual' tensions with pharmacy benefit managers and payers.
You may also be interested in...
Novo Nordisk’s new India managing director takes charge amid heightened competition in the diabetes space. The Danish firm stays committed to bringing new products to this market at a faster clip and all eyes will be on the launch trajectory of therapies like semaglutide.
Cardiovascular outcome trials are driving development in blockbuster SGLT-2 inhibitor and GLP-1 agonist classes to look beyond HbA1c levels to focus on cardiovascular and renal protective effects.
A 30-day supply of the first oral GLP-1 agonist will cost $772.43 in the US, similar to the injectable version but steeper than oral diabetes medicines. Deep discounts may be needed to secure market access.